IndustryCompany release

Indivior reports record Sublocade sales as Supernus merger nears 2 November close

🇺🇸 Indivior Pharmaceuticals, Inc. (INDV) · Thu 29 Oct 2026

Indivior's third-quarter revenue rose 13% to $356m, driven by a 22% rise in Sublocade sales, with the all-stock Supernus deal expected to complete on 2 November.

Indivior Pharmaceuticals announced results for the quarter ended 30 September 2026 on 29 October. Net revenue came to $356m, up 13%. Net income was $137m and adjusted EBITDA reached $211m.

Sublocade, the company's treatment for opioid use disorder, was the main contributor. Sales reached a record $267m, an increase of 22%.

Indivior also gave an update on its all-stock merger with Supernus, which shareholders approved in October. The company expects the transaction to close on 2 November 2026. After completion, the combined company will trade under the ticker SUPN.

The announcement summary does not provide further detail on the integration plans, the terms of the merger or the company's outlook, so these are not covered here.

What it means for your team

  • Market-access teams tracking opioid use disorder treatments should note Sublocade's continued growth, with record quarterly sales of $267m.
  • Regulatory and pharmacovigilance contacts at Indivior and Supernus may see organisational changes once the merger completes on 2 November; companies often update marketing authorisation holder details and safety contacts after such transactions.
  • Teams that deal with either company should watch for announcements on the combined entity's structure and its new SUPN listing.

Company's press release (SEC filing): Indivior Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Indivior Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →